FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115006390> ?p ?o ?g. }

• W2115006390 abstract "In several open-label studies, recombinant human interleukin 10 (rhIL-10), a type 2 anti-inflammatory cytokine, has been reported to improve psoriasis, a disease characterized by type 1 cytokine inflammation.To evaluate the safety, efficacy, and immunologic parameters in individuals with psoriasis treated with rhIL-10.Patients received rhIL-10 (20 micro g/kg) or placebo subcutaneously 3 times weekly for 12 weeks in a randomized, double-blind manner.National Institutes of Health Clinical Center in Bethesda. Twenty-eight patients with moderate-to-severe psoriasis as defined by a Psoriasis Area Severity Index (PASI) score of 10 or higher.The primary clinical end point was the mean percentage change in the PASI score comparing baseline and week 12 scores. Intracellular cytokine production by peripheral blood mononuclear cells (PBMCs) was measured by flow cytometry.There was no significant difference in the mean percentage change in the PASI score from baseline to week 12 between the rhIL-10-treated group and control patients (17% vs 13% improvement, respectively; P =.69), although a modest trend toward improvement in patients receiving rhIL-10 was documented at both the 6- and 8-week points. Interestingly, proinflammatory and type 1 cytokine production by PBMCs progressively declined in the rhIL-10-treated patients during the entire 12-week study period.Treatment with rhIL-10 resulted in only temporary clinical improvement in psoriasis, despite sustained systemic decreases in proinflammatory and type 1 cytokine production. These data suggest that immunotherapy that decreases the ratio of systemic type 1 and type 2 cytokine production does not necessarily lead to improvement of type 1 cytokine-mediated disease." @default.
• W2115006390 created "2016-06-24" @default.
• W2115006390 creator A5018235766 @default.
• W2115006390 creator A5041023733 @default.
• W2115006390 creator A5044239219 @default.
• W2115006390 creator A5046042231 @default.
• W2115006390 creator A5048960816 @default.
• W2115006390 creator A5059096564 @default.
• W2115006390 creator A5059337854 @default.
• W2115006390 creator A5060729846 @default.
• W2115006390 creator A5080237247 @default.
• W2115006390 date "2002-10-01" @default.
• W2115006390 modified "2023-10-17" @default.
• W2115006390 title "Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10" @default.
• W2115006390 cites W1515615230 @default.
• W2115006390 cites W1556474055 @default.
• W2115006390 cites W1560264230 @default.
• W2115006390 cites W1579662602 @default.
• W2115006390 cites W1977336467 @default.
• W2115006390 cites W1999202157 @default.
• W2115006390 cites W2000076767 @default.
• W2115006390 cites W2015548386 @default.
• W2115006390 cites W2019276276 @default.
• W2115006390 cites W2022253360 @default.
• W2115006390 cites W2024174668 @default.
• W2115006390 cites W2025046126 @default.
• W2115006390 cites W2027812158 @default.
• W2115006390 cites W2041635511 @default.
• W2115006390 cites W2049702967 @default.
• W2115006390 cites W2055568545 @default.
• W2115006390 cites W2056782245 @default.
• W2115006390 cites W2071715360 @default.
• W2115006390 cites W2085110576 @default.
• W2115006390 cites W2089323062 @default.
• W2115006390 cites W2105794134 @default.
• W2115006390 cites W2110200062 @default.
• W2115006390 cites W2285666375 @default.
• W2115006390 cites W2306744213 @default.
• W2115006390 doi "https://doi.org/10.1001/archderm.138.10.1341" @default.
• W2115006390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12374540" @default.
• W2115006390 hasPublicationYear "2002" @default.
• W2115006390 type Work @default.
• W2115006390 sameAs 2115006390 @default.
• W2115006390 citedByCount "64" @default.
• W2115006390 countsByYear W21150063902013 @default.
• W2115006390 countsByYear W21150063902014 @default.
• W2115006390 countsByYear W21150063902016 @default.
• W2115006390 countsByYear W21150063902017 @default.
• W2115006390 countsByYear W21150063902018 @default.
• W2115006390 countsByYear W21150063902019 @default.
• W2115006390 countsByYear W21150063902020 @default.
• W2115006390 countsByYear W21150063902021 @default.
• W2115006390 countsByYear W21150063902023 @default.
• W2115006390 crossrefType "journal-article" @default.
• W2115006390 hasAuthorship W2115006390A5018235766 @default.
• W2115006390 hasAuthorship W2115006390A5041023733 @default.
• W2115006390 hasAuthorship W2115006390A5044239219 @default.
• W2115006390 hasAuthorship W2115006390A5046042231 @default.
• W2115006390 hasAuthorship W2115006390A5048960816 @default.
• W2115006390 hasAuthorship W2115006390A5059096564 @default.
• W2115006390 hasAuthorship W2115006390A5059337854 @default.
• W2115006390 hasAuthorship W2115006390A5060729846 @default.
• W2115006390 hasAuthorship W2115006390A5080237247 @default.
• W2115006390 hasBestOaLocation W21150063901 @default.
• W2115006390 hasConcept C126322002 @default.
• W2115006390 hasConcept C137061746 @default.
• W2115006390 hasConcept C142724271 @default.
• W2115006390 hasConcept C164027704 @default.
• W2115006390 hasConcept C185592680 @default.
• W2115006390 hasConcept C202751555 @default.
• W2115006390 hasConcept C203014093 @default.
• W2115006390 hasConcept C204787440 @default.
• W2115006390 hasConcept C27081682 @default.
• W2115006390 hasConcept C2776914184 @default.
• W2115006390 hasConcept C2777011040 @default.
• W2115006390 hasConcept C2778690821 @default.
• W2115006390 hasConcept C2780564577 @default.
• W2115006390 hasConcept C47348012 @default.
• W2115006390 hasConcept C535046627 @default.
• W2115006390 hasConcept C55493867 @default.
• W2115006390 hasConcept C71924100 @default.
• W2115006390 hasConcept C90924648 @default.
• W2115006390 hasConceptScore W2115006390C126322002 @default.
• W2115006390 hasConceptScore W2115006390C137061746 @default.
• W2115006390 hasConceptScore W2115006390C142724271 @default.
• W2115006390 hasConceptScore W2115006390C164027704 @default.
• W2115006390 hasConceptScore W2115006390C185592680 @default.
• W2115006390 hasConceptScore W2115006390C202751555 @default.
• W2115006390 hasConceptScore W2115006390C203014093 @default.
• W2115006390 hasConceptScore W2115006390C204787440 @default.
• W2115006390 hasConceptScore W2115006390C27081682 @default.
• W2115006390 hasConceptScore W2115006390C2776914184 @default.
• W2115006390 hasConceptScore W2115006390C2777011040 @default.
• W2115006390 hasConceptScore W2115006390C2778690821 @default.
• W2115006390 hasConceptScore W2115006390C2780564577 @default.
• W2115006390 hasConceptScore W2115006390C47348012 @default.
• W2115006390 hasConceptScore W2115006390C535046627 @default.
• W2115006390 hasConceptScore W2115006390C55493867 @default.
• W2115006390 hasConceptScore W2115006390C71924100 @default.
• W2115006390 hasConceptScore W2115006390C90924648 @default.

• next